Samsung Biologics Co Ltd Cash Flow Reinvestment Rate
Samsung Biologics Co Ltd cash flow reinvestment rate. Samsung Biologics Co Ltd (207940) has a Cash Flow Reinvestment Rate of 1.44x as of June 2026, reinvesting ₩898.75 Billion (capex ₩99.08 Billion plus investments ₩-799.67 Billion) from operating cash flow of ₩624.80 Billion. Explore Samsung Biologics Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Samsung Biologics Co Ltd (2017–2025)
Cash flow reinvestment rate of Samsung Biologics Co Ltd from 2017 to 2025. Historical reinvestment intensity for Samsung Biologics Co Ltd across 8 annual periods. Explore 207940 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Samsung Biologics Co Ltd Cash Flow Reinvestment Rate by Year (2017–2025)
Samsung Biologics Co Ltd cash flow reinvestment rate by year from 2017 to 2025. Year-by-year capital reinvestment analysis for Samsung Biologics Co Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Samsung Biologics Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.84x | ₩1.88 Trillion | ₩2.25 Trillion | ₩1.48 Trillion | ▼ -34.6% |
| 2024 | 1.28x | ₩2.12 Trillion | ₩1.66 Trillion | ₩1.38 Trillion | ▼ -20.2% |
| 2023 | 1.60x | ₩2.67 Trillion | ₩1.67 Trillion | ₩1.11 Trillion | ▼ -22.5% |
| 2022 | 2.07x | ₩1.97 Trillion | ₩953.05 Billion | ₩956.84 Billion | ▲ +2.4% |
| 2021 | 2.02x | ₩918.63 Billion | ₩454.60 Billion | ₩406.25 Billion | ▼ -0.4% |
| 2020 | 2.03x | ₩409.83 Billion | ₩202.09 Billion | ₩139.66 Billion | ▼ -97.2% |
| 2019 | 72.36x | ₩734.74 Billion | ₩10.15 Billion | ₩192.84 Billion | ▲ +757.6% |
| 2017 | 8.44x | ₩1.26 Trillion | ₩149.82 Billion | ₩494.12 Billion | — |